MAIA (MAIA Biotechnology) EBIT per Share : $-1.38 (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology EBIT per Share?

MAIA Biotechnology's EBIT per Share for the three months ended in Sep. 2024 was $-0.12. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.38.

During the past 3 years, the average EBIT per Share Growth Rate was -32.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MAIA Biotechnology's EBIT per Share or its related term are showing as below:

MAIA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -32 Med: -32 Max: -32
Current: -32

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of MAIA Biotechnology was -32.00% per year. The lowest was -32.00% per year. And the median was -32.00% per year.

MAIA's 3-Year EBIT Growth Rate is ranked worse than
83.65% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs MAIA: -32.00

MAIA Biotechnology's EBIT for the three months ended in Sep. 2024 was $-2.74 Mil.

MAIA Biotechnology EBIT per Share Historical Data

The historical data trend for MAIA Biotechnology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology EBIT per Share Chart

MAIA Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.65

-1.11

-1.70

-1.49

MAIA Biotechnology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial											-0.36	-0.40	-0.46	-0.40	-0.12

MAIA Biotechnology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MAIA Biotechnology's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-19.766	/	13.262
=	-1.49

MAIA Biotechnology's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.736	/	23.895
=	-0.11

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.38

MAIA Biotechnology (AMEX:MAIA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MAIA Biotechnology EBIT per Share Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MAIA Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060

Website

https://www.maiabiotech.com

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Executives

Steven M Chaouki	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Stan Smith	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ramiro Guerrero	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie	director, 10 percent owner	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc	director, 10 percent owner, officer: Chief Executive Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire	officer: Chief Financial Officer	6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Jean-manasse Theagene	director	500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Sergei Gryaznov	officer: Chief Scientific Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea	officer: Chief Medical Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606